Abstract
Payers & Health Technology Assessment bodies (HTA) are faced with an increasingly complex healthcare landscape with treatments that are increasingly effective. Taking into Quality of Life (QoL) is becoming a new parameter in the evaluation of treatments' value. However, this seems difficult to achieve in France. We aimed to identify obstacles and potential opportunities by comparing three health systems.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
